Prediction and Prevention of Twin Premature Birth 2021 | NCT05061641 | Trialant

Prediction and Prevention of Twin Premature Birth 2021 | NCT05061641 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
progesterone 200mg	Active Comparator	Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 200mg	Drug: Progesterone
progesterone 400mg	Experimental	Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 400mg	Drug: Progesterone
progesterone 600mg	Experimental	Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 600mg	Drug: Progesterone

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Progesterone	Drug	The delivery outcomes of the three groups were compared, including the rate of premature delivery (<37 weeks of gestation), the rate of early premature delivery (<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (<37 weeks), neonatal perinatal mortality and morbidity.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Neonatal prognosis	Preterm birth rate (<37 weeks of gestation), early preterm birth rate (<32 weeks of gestation), need to receive anti-tocolytic treatment; Rates of premature rupture of membranes (<37 weeks), neonatal perinatal mortality and morbidity.	one week

Secondary Outcomes

Measure	Description	Time Frame
Gestational age and prolongation of gestational age at delivery	Gestational age at which symptoms of preterm birth occur and gestational age at delivery after treatment	one year

Contacts/Locations Module

Condition Browse Module

Intervention Browse Module